Citadel Advisors’s Impact BioMedical IBO Stock Holding History

Citadel Advisors’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-60,315	Closed	-$52.5K	–	15612
2025 Q1	$52.5K	Buy	+60,315	New	+$104K	﹤0.01%	12268

Other funds holding IBO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Citadel Advisors's IBO Position: Q2 2025 in Review

Citadel Advisors sold out of Impact BioMedical (IBO) in Q2 2025, closing a stake of 60,315 shares — an estimated $52.5K sold.

Citadel Advisors first reported a position in IBO in Q1 2025 and held it in 1 quarter. The position peaked at $52.5K in Q1 2025. 19 funds tracked by Wall St. Rank hold IBO as of Q2 2025.

Citadel Advisors reported no remaining Impact BioMedical position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 60,315 Impact BioMedical shares in Q2 2025, an estimated $52.5K.
Citadel Advisors first reported a position in Impact BioMedical in Q1 2025 and held it in 1 quarter.
Citadel Advisors's Impact BioMedical position peaked at $52.5K in Q1 2025.
19 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.